Clinical trials: Schizophrenia Spectrum Disorders
Schizophrenia
Effects of Intranasal Oxytocin on Satiety Signaling in People With Schizophrenia
The objective of this study is to test a single dose of intranasal oxytocin, compared to placebo, in a within subjects, crossover design, to see if oxytocin will improve satiety signaling (behaviorally and/or by self report)…
- Trial name
- NCT01614093
- Testing
- Oxytocin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Maryland, Baltimore
Tobacco Dependence, Schizophrenia
Cigarette Smoking in Smokers With and Without Schizophrenia
Higher rates and severity of tobacco dependence in people with schizophrenia, as compared with the general population, contribute to the lower life expectancy seen in this population.
- Trial name
- NCT04001114
- Testing
- Sampling Research Cigarettes
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Schizophrenia
A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-02545920 In Psychiatrically Stable Subjects With Schizophrenia
To evaluate the safety and tolerability of multiple doses of PF 02545920 administered orally to psychiatrically stable subjects with schizophrenia receiving background antipsychotic +/- other adjunctive medication.
- Trial name
- NCT01829048
- Testing
- PF-02545920
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Pfizer
Schizophrenia
Trial of D-Cycloserine in Schizophrenia
To characterize further the effects of D-cycloserine augmentation of antipsychotic treatment on negative symptoms, performance on neurocognitive tasks, and on markers for glutamatergic, dopaminergic and serotonergic function in…
- Trial name
- NCT00000371
- Testing
- D-cycloserine
- Volunteers
- 60 people
- Sponsor
- Massachusetts General Hospital
Suicide, Psychosis
Cognitive Behavioral Suicide Prevention for Psychosis: Aim 1
The investigators are modifying and testing the preliminary effectiveness and implementation of a Cognitive Behavioral Suicide Prevention for psychosis (CBSPp) intervention.
- Trial name
- NCT04689867
- Testing
- Cognitive Behavioral Suicide Prevention for psychosis CBSPp)
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Michigan
Randomized Controlled Trial
Exploring the Effect of Rumination-Focused Cognitive Behaviour Therapy in Patients With Schizophrenia
This study will explore the effect of Rumination-Focused Cognitive Behaviour Therapy on depressive symptoms in patients with schizophrenia for three months.
- Trial name
- NCT04442893
- Testing
- Rumination-Focused Cognitive Behaviour Therapy, Health Education programme
- Where
- Taiwan
- Volunteers
- 85 people
- Sponsor
- National Yang Ming Chiao Tung University
Schizoaffective Disorder, Schizophrenia
Effectiveness of a Mobile Texting Intervention for People With Serious Mental Illness
Testing an mHealth mobile interventionist texting program on illness management.
- Conditions
- Schizoaffective Disorder, Schizophrenia, Bipolar Disorder, Major Depressive Disorder
- Trial name
- NCT03062267
- Testing
- Mobile Interventionist
- Where
- 2 sites in United States
- Volunteers
- 49 people
- Sponsor
- University of Washington
Schizophrenia
Multiple Ascending Doses of PF-04958242 in Subjects With Stable Schizophrenia
This study aims to assess the safety, tolerability and pharmacokinetics of PF-04958242 in multiple ascending doses in subjects with stable schizophrenia.
- Trial name
- MAD (NCT02332798)
- Testing
- PF-04958242
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Biogen
Schizophrenia
A Study of the Efficacy and Safety of Asenapine in Participants With an Acute Exacerbation of Schizophrenia (P05688)
The purpose of this trial is to assess the effect of asenapine 2.5 and 5 mg sublingually twice daily (BID) compared with placebo in the treatment of schizophrenia (overall symptoms) as measured by the Positive and Negative…
- Trial name
- NCT01617187
- Testing
- Asenapine, Olanzapine
- Volunteers
- 360 people
- Sponsor
- Organon and Co
Schizophrenia and Predominant Negative Symptoms
Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and Predominant Negative Symptoms
To explore the efficacy of SPD489, as adjunctive therapy to a stable dose of atypical antipsychotic medication, on negative symptoms in adult subjects with clinically stable schizophrenia and predominant negative symptoms, as…
- Trial name
- NCT00922272
- Testing
- SPD489 (lisdexamfetamine dimesylate)
- Where
- 27 sites in United States
- Volunteers
- 92 people
- Sponsor
- Shire
Schizophrenia
Double Blind, Randomized, 3 Week Inpatient Study To Evaluate The Safety & Efficacy Of PF-02545920 Compared With Placebo
To assess the efficacy and safety of an investigational compound PF-02545920 for the treatment of schizophrenia. PF-02545920 will be more effective than placebo in reducing symptoms associated with schizophrenia.
- Trial name
- NCT00570063
- Testing
- PF-02545920
- Where
- 10 sites in United States
- Volunteers
- 35 people
- Sponsor
- Pfizer
Schizophrenia, Cognition
Curcumin as a Novel Treatment to Improve Cognitive Dysfunction in Schizophrenia
The investigators propose to test whether curcumin nanoparticles will improve behavioral measures and biomarkers of cognition and neuroplasticity in patients with schizophrenia who are already receiving a stable dose of…
- Conditions
- Schizophrenia, Cognition, Psychosis
- Trial name
- NCT02104752
- Testing
- Curcumin
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- VA Greater Los Angeles Healthcare System
Schizophrenia, Bipolar Disorder
Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine
The purpose of this study is to assess the efficacy of d-cycloserine (DCS) as an augmentation strategy in two psychotic patients with a triplication (4 copies) of the glycine decarboxylase (GLDC) gene.
- Trial name
- DCS (NCT02304432)
- Testing
- D-cycloserine
- Volunteers
- 2 people
- Sponsor
- Mclean Hospital
Psychiatric Illness, Healthy
Effects of GLYX-13 on Learning and Memory in Healthy Individuals and Those With Psychiatric Illness
The present study proposes to evaluate the potential cognitive enhancing effects of GLYX-13, an NMDAR partial agonist, among a group of healthy adults and those with psychiatric illness on a series of functional magnetic…
- Trial name
- NCT01844726
- Testing
- GLYX-13
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Northwestern University
Schizophrenia, Schizoaffective Disorder
Cognitive-Behavioral Therapy in Veterans With Schizophrenia
This is a study comparing the benefits of two types of individual psychotherapy (cognitive-behavioral therapy for psychosis and supportive therapy) in symptomatic Veteran outpatients diagnosed with schizophrenia or…
- Trial name
- NCT00688259
- Testing
- Supportive Therapy (ST), Cognitive Behavioral Therapy for Psychosis (CBTp)
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- VA Office of Research and Development
Schizophrenia Schizoaffective
Clozapine CHAMPION-ECHO Educational Study to Improve Clozapine Use.
In a randomized controlled design with approximately 26 biweekly sessions over 12 months, the investigators propose to test the effectiveness of an ECHO-based intervention for improving the use of clozapine in people eligible for…
- Trial name
- CHAMPION (NCT04325386)
- Testing
- ECHO Intervention, eTAU
- Where
- United States
- Volunteers
- 266 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Schizophrenia, Tobacco Use
Minocycline and Tobacco Craving in Smokers With Schizophrenia
Craving for cigarettes is an important aspect that leads to challenges with smoking cessation. Persons with schizophrenia are more likely to smoke and to be heavier smokers than persons without schizophrenia, and may experience…
- Trial name
- NCT02968602
- Testing
- Minocycline
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Maryland, Baltimore
Psychosis
Effectiveness of Cognitive Remediation in a Supported Education Setting
The purpose of this study is to determine whether cognitive remediation as an adjunct to supported education, will result in improved cognitive functioning, symptoms, and performance in academic domains for persons with psychosis…
- Trial name
- NCT01492439
- Testing
- Cognitive Remediation, Supported Education
- Where
- 2 sites in Canada
- Volunteers
- 37 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia
Safety, Tolerability, and Pharmacokinetics Study of Elpipodect (MK-8189) in Participants With Schizophrenia and Healthy Participants (MK-8189-011)
This is a randomized, double-blind, 2-part clinical study of the safety, tolerability and pharmacokinetics of alternate elpipodect titration regimens.
- Trial name
- NCT04506905
- Testing
- Elpipodect
- Where
- 6 sites in United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Schizophrenia
Aerobic Exercise for Cognition in Schizophrenia
This study will evaluate the ability of aerobic exercise (AE) to improve cognition in people with schizophrenia. Participants will be randomly assigned to one of two interventions: (1) aerobic exercise class (stationary bicycle…
- Trial name
- NCT02621983
- Testing
- Aerobic Exercise, Balance and Stretching
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- VA Office of Research and Development